

**In the Claims**

Please cancel claims 24, 27, 36, 40, 45, 50, 55, 60, 65, 70 and 77-84.

Please add new claims 85-105.

Please re-write the claims as indicated below.

1. (Original) A method of enhancing migration of CaR receptor expressing cells to a specific site in a subject, comprising:

locally administering to a specific site in a subject in need of such treatment a nonCa<sup>++</sup> CaR receptor agonist in an amount effective to enhance migration of CaR receptor expressing cells to the specific site in the subject.

10. (Original) A method of inhibiting migration of CaR receptor expressing cells to a specific site in a subject, comprising:

locally administering to a specific site in a subject in need of such treatment a CaR receptor antagonist in an amount effective to inhibit migration of CaR receptor expressing cells to the specific site in the subject.

85. (New) The method of claim 1, wherein the CaR receptor expressing cells are hematopoietic cells.

86. (New) The method of claim 2, wherein the hematopoietic cells are hematopoietic progenitor cells.

87. (New) The method of claim 1, wherein the CaR receptor expressing cells are neural cells.

88. (New) The method of claim 1, wherein the CaR receptor expressing cells are epithelial cells.

89. (New) The method of claim 1, wherein the CaR receptor expressing cells are mesenchymal cells.

90. (New) The method of claim 1, wherein the CaR receptor expressing cells are endothelial cells.

91. (New) The method of claim 1, wherein the nonCa<sup>++</sup> CaR receptor agonist is NPS R-467.

92. (New) The method of claim 1, wherein the nonCa<sup>++</sup> CaR receptor agonist is NPS S-467.

93. (New) The method of claim 10, wherein the specific site is a site of inflammation.

94. (New) The method of claim 93, further comprising co-administering a non-CaR receptor antagonist that inhibits migration of immune cells to the site of inflammation in the subject.

95. (New) The method of claim 94, wherein the non-CaR receptor antagonist is an antiinflammatory agent.

96. (New) The method of claim 10, wherein the subject has an autoimmune disease.

97. (New) The method of claim 96, wherein the autoimmune disease is rheumatoid arthritis, uveitis, insulin-dependent diabetes mellitus, hemolytic anemias, rheumatic fever, Crohn's disease, Guillain-Barre syndrome, psoriasis, thyroiditis, Graves' disease, myasthenia gravis, glomerulonephritis, autoimmune hepatitis, or systemic lupus erythematosus.

98. (New) The method of claim 10, wherein the subject has an abscess, a transplant, an implant, atherosclerosis, or myocarditis.

99. (New) The method of claim 10, wherein the CaR receptor expressing cells are hematopoietic cells.

100. (New) The method of claim 99, wherein the hematopoietic cells are hematopoietic progenitor cells.

101. (New) The method of claim 10, wherein the CaR receptor expressing cells are neural cells.

102. (New) The method of claim 10, wherein the CaR receptor expressing cells are epithelial cells.

103. (New) The method of claim 10, wherein the CaR receptor expressing cells are mesenchymal cells.

104. (New) The method of claim 10, wherein the CaR receptor expressing cells are endothelial cells.

105. (New) The method according to any of claims 10 or 93-104, wherein the CaR receptor antagonist is NPS-2143.